GLP-1 medications such as Wegovy, Ozempic, and Mounjaro have already reshaped the way clinicians manage long-term conditions like obesity and type 2 diabetes, and researchers think their impact could extend well beyond weight and blood sugar.
Over the past few years, multiple trials have reported additional health improvements in people taking semaglutide and related drugs—benefits that aren’t directly tied to the original reason the medication was prescribed.
Some early findings have pointed to potential risk reductions in several major causes of death, including cardiovascular disease and dementia, suggesting that GLP-1 therapies may influence multiple body systems at once.
Now, an attention-grabbing update presented by the American Society of Clinical Oncology indicates these broader effects could also be relevant in oncology, with new data suggesting GLP-1 drugs may be linked to slower cancer progression in several tumor types.
To explore the question, researchers used the TriNetX Global Health Research Network, comparing cancer outcomes in patients using GLP-1 drugs against outcomes in patients taking DPP-4 inhibitors, a commonly used class of medications for type 2 diabetes.
Mark David Orland of Cleveland Clinic’s Taussig Cancer Institute, said: “Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types.”
The analysis drew on medical records from around 12,000 people diagnosed with one of seven cancers, spanning stages one through three. The cancers assessed included breast, prostate, lung, colorectal, liver, kidney, and pancreatic cancer.
According to the results, metastatic progression occurred less often among GLP-1 users in six of the seven cancer groups studied. Kidney cancer was the exception, where the dataset did not show the same reduction.
Four cancers in particular—lung, breast, colorectal, and liver—showed what researchers described as a ‘statistically significant’ slowdown in spread compared with patients taking DPP-4 inhibitors. According to NBC analysis, the strongest associations were seen in lung and breast cancer: lung cancer patients had a 50 percent lower chance of progressing to stage four, while breast cancer patients saw a 43 percent reduction.
Marcin Chwistek, MD, FAAHPM, Chief of the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center commented on the study, remarking: “GLP-1 RAs have never been just glucose-lowering drugs.
“Their anti-inflammatory and immune-modulatory properties have long suggested broader effects. What’s new here is the consistency across tumor types, and data this large and this consistent warrant a prospective randomized trial.”
Because the work was observational—based on records rather than an experiment designed to test cause and effect—the authors emphasized the need for randomized clinical trials to confirm the relationship and to pinpoint the biological mechanism that might explain why GLP-1 drugs appear to influence progression in some cancers.